Ferrer Internacional, S.a.

Ferrer International, S.a.

Bioprojet

Argenx Bv

Nicox S.a.

Antonio Guglietta

Albert Palomer

Luis Anglada

José Luís Falcó

Benjamin Santos

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Francesca Benedini

Ennio Ongini

Manuel M Raga

Xavier Ligneau

Walter Schunack

Jean-Michel Arrang

Holger Stark

Juan Sallares

Cristina Tarragó

Marta Guerrero

Charon Ganellin

Rafael Foguet

Torsten Dreier

Peter Ulrichts

Jorge Ramentol

Lluis Anglada

Johannes De Haard

Nicolas Leupin

Montserrat Cano

Josep Lluis Falco

Marta Princep

Celia Palacin

Anna Orriols

José L Falcó

José Falcó

Manuel Raga

Alfonso Romero

Daniel Palop

José Luis Falcó

Carlos Albet

Luís Anglada

Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.

Use of FCRN antagonists for treatment of generalized myasthenia gravis

The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R, X and Y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (I) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic procedures for preparing said compounds and certain intermediates, as well as intermediates themselves. 

Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines

The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Pharmaceutical topical compositions

The invention provides novel imidazo[1,2-b]pyridazines of formula (I) and pharmaceutically acceptable salts, polymorphs, hydrates, tautomers, solvates and stereoisomers thereof. Compounds of formula (I) are useful for treating or preventing diseases associated with GABAreceptors modulation, anxiety, epilepsy, sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic procedures for preparing said compounds and certain intermediates, as well as intermediates themselves. 

Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions

Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

The present invention relates to an amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, methods for its preparation, its use as a therapeutically active agent and pharmaceutical compositions comprising the novel form.

[object Object]

The present invention relates to a method of treating anxiety, epilepsy, sleep disorders, and insomnia, for inducing sedation-hypnosis, anesthesia, and muscle relaxation, and for modulating the necessary time to induce sleep and its duration, which comprises administering a therapeutically effective amount of Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide characterized by a powder X-Ray diffraction pattern containing specific peaks at 2&#x3b8;=7.1&#xb0; (&#xb1;0.1&#xb0;) and 21.4&#xb0; (&#xb1;0.1&#xb0;) to a patient in need thereof.

Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide

The invention provides new compounds of formula (I) wherein R, R, R, R, and X have different meanings. Preparative processes, pharmaceutical compositions, and uses thereof in the treatment or prevention of conditions mediated by melatonin receptors are also provided. 

The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine

The invention provides novel pyrazolo[1,5-a]pyrimidines which are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.

The present invention relates to a novel polymorph of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, processes for its preparation, its use as a medicament, its use in the manufacture of a medicament, and pharmaceutical compositions comprising the novel polymorph.

Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide

Growing community of inventors

Barcelona, Spain

Antonio Guglietta